We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
M. Scott Lucia

M. Scott Lucia MD

Professor and Vice Chair of Anatomic Pathology, Chief of Genitourinary Pathology, Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO
Scott Lucia, MD is Professor and Vice Chair of Anatomic Pathology and Chief of Genitourinary and Renal Pathology at the University of Colorado Anschutz Medical Campus (UCAMC) School of Medicine where he also serves as the Director UCAMC Biorepository Core Facility. Dr. Lucia received his MD from the University of Colorado School of Medicine in 1988. He completed his internship and residency in pathology at the University of Colorado in 1993. He was a research fellow in the Laboratory of Chemoprevention at the National Institutes of Health from 1993 to 1995 before returning to the University of Colorado in 1995.

Dr. Lucia served as the primary pathologist for the Prostate Cancer Prevention Trial (PCPT) and Vitamin E and Selenium Chemoprevention Trial (SELECT), sponsored by the Southwest Oncology Group, the Medical Therapy of Prostate Symptoms (MTOPS) trial, sponsored by the NIDDK, and the Reduction with Dutasteride of Clinical Progression Events in Expectant Management of Prostate Cancer (REDEEM) sponsored by GlaxoSmithKline. He directs the operation of several tissue and serum biorepositories for prostate and prostatic diseases including those for the PCPT, MTOPS, SELECT, and the University of Colorado Cancer Center Prostate Biorepository. He has authored or co-authored over 160 peer-reviewed articles, reviews, editorials and/or book chapters. His primary areas of interest include pathology of prostate cancer and hyperplasia, early detection and prevention of prostate cancer, prostate cancer biomarkers, and mechanisms of carcinogenesis.


Part owner of the startup company, 3DBiopsy, that produces materials (registration software, biopsy collection kits and needles) to aid physicians in improved targeted focal therapy.